We promote collaboration and scientific excellence, while exploring the amazing nature of our immune system and harnessing its power for the development of new treatments, for the benefit of humanity.
Our research
Dysregulation of immunity, in the form of immunodeficiency or immune over-activation can lead to life-threatening sepsis or the emergence of devastating autoimmune disease. In the past decade, immune system function was discovered to also impact “non-immune” diseases such as cancer, obesity, and even neuro-degenerative disease. Innovative immune interventions constitute the forefront of medical treatment, with examples spanning vaccination in COVID, immunomodulatory treatment in Inflammatory Bowel Disease (IBD), and cancer immunotherapy transforming the treatment of a variety of malignancies.
The Department of Systems immunology has formed a first-of-its-kind home to inter-disciplinary research integrating immunology with diverse disciplines that span genomics, proteomics, computational biology, metabolism, neurology, microbiology, cancer research and medicine. We strive to develop a vibrant and inclusive community of researchers of diverse backgrounds that will advance science, medicine, and biotechnology for the benefit of humans and their environment.
News
New Article published in Immunity by The Shulman Lab
High-grade serous ovarian cancer (HGSOC) is an extremely lethal cancer originating from the ovary or secretory cells within the fallopian tube and is typically diagnosed at an advanced stage. Immune cells, including myeloid cells, T cells, B cells, and plasma cells (PCs), infiltrate HGSOC to varying degrees, yet fail to effectively eradicate the tumor. The presence of B cells and PCs in various tumors, including HGSOC, has been associated with a favorable prognosis and improved response to immunotherapy, leading to a growing interest in B cell functions in tumors. Tumor-infiltrating B cells can generate tumor-reactive antibodies that have the potential to mediate tumor killing and phagocytosis by innate cells. Furthermore, B cells can present antigens to CD4 T cells, which can further boost the immune response against tumors.
New Article published in PLOS Biology by The Shachar Lab
The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis.